Illumina and the Minderoo Foundation said on Tuesday that they have signed a partnership to commit A$40 million ($27.8 million) towards sequencing DNA in marine systems.

Ginkgo Bioworks reported after the close of the market on Monday that its second quarter 2022 revenues grew 231 percent year over year, driven by biosecurity service revenues.

August 11, the Second Roche Pan-Tumor Precision Diagnosis and Innovation Ecology Forum was officially opened at Roche Pharma China Shanghai Campus, where participants discussed solutions for pan-tumor precision diagnosis and treatment.

Becton Dickinson announced on Monday that it has inked a deal with Accelerate Diagnostics to sell that firm's Accelerate Pheno system and the Accelerate Arc module for antimicrobial susceptibility testing.

The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors.

Kingmed and Cephei China dsigned a strategic cooperation agreement in Guangzhou to jointly promote the accurate diagnosis of clinical infectious diseases such as tuberculosis, hospital-acquired infection, drug-resistant bacterial infection, and carry out long-term in-depth cooperation.

Guardant Health and Thermo Fisher Scientific said on Friday that the US Food and Drug Administration has granted premarket approvals for their respective next-generation sequencing assays as companion diagnostics to Enhertu (trastuzumab deruxtecan)

Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai said on Friday that they have launched a new large-scale human genome sequencing research project with New York-based biotechnology company Regeneron.

According to the news on August 8, Beijing Savant Biotechnology Co., ltd. (Stock Code No.: 873748) was listed on the New OTC Market.

Lucira Health announced on Thursday that it has received authorization under an interim order from Health Canada to market the Lucira COVID-19 & Flu Test for emergency use.

Roche announced on Thursday that it has received approval from the US Food and Drug Administration for a label expansion of its Ventana MMR RxDx Panel to determine which solid tumor patients could benefit from treatment with Merck's Keytruda (pembrolizumab).

Recently, Suzhou Hybiome Biomedical Engineering Co., Ltd. announced the completion of the Pre-IPO round of financing with CNY 100 million. Huatai United Securities acted as the financial advisor in this transaction and introduced investor Zhongrong Trust Dingxin to Hybiome.

Becton Dickinson announced on Tuesday that it has signed a collaboration agreement with Laboratory Corporation of America to develop flow cytometry-based companion diagnostics.

Molecular testing company Predicine said on Tuesday that its blood and urine cell-free DNA (cfDNA) assay, PredicineCare, has secured a CE-IVD mark.

Recently, the localization project of QIAGEN has received another good news. The automatic nucleic acid extraction instrument QIAcube HT has been received the first-class medical device filing approval